MA-VALIDITY
Validity , the most trusted name in customer data quality, announced today that it has entered into a definitive agreement to acquire email analytics and deliverability provider 250ok. Since 2011, 250ok has developed email management software and innovative tools used by businesses of every size. With this acquisition, Validity broadens its optimization capabilities across the global ecosystem of email service providers.
Email remains a critical channel for marketers to attract and engage customers. However, keeping messages out of the spam folder and delighting recipients continues to be a challenge. Mailbox providers work hard to protect users from spam and threats, and inboxes are crowded with unoptimized, spray-and-pray approaches to marketing. Without the right data, tools and guidance, even the best emailers can struggle to reach the inbox and have impact. For online retailers, staying out of the spam folder has a dramatic impact on revenue opportunities and conversion. 250ok enables marketers to get more email delivered, the right way to targeted recipients, and enjoy greater conversion and return on investment as a result.
250ok began innovating in the analytics and deliverability software market in 2011. The company was started by former ExactTarget email deliverability expert Greg Kraios. Today 250ok revolutionizes email management software by creating innovative tools for modern email senders, including Marketo, CDW, National Geographic, Crutchfield, Furniture Row, and PETA. With this acquisition, Validity brings together some of the top talent in the email industry to help ensure messages stay out of the spam folder.
“Amongst the many players in the email market, the 250ok team is such a perfect fit within the Validity family,” said Mark Briggs, chairman and CEO of Validity. “Our combined analytics platform, email expertise, and reach across the broadest set of email service providers brings enormous value to marketers across the world.”
Many of Validity’s largest email customers use both 250ok and Return Path from Validity to optimize their email campaigns. With this acquisition, the Validity for Email solution is strengthened with 250ok technologies and services, including:
- Deliverability and Reputation
- Engagement Analytics
- DMARC Deployment
- Design Previews
- List Validation
“For these last several years, we have been working hard to stand out in this crowded market by creating the best products for email marketers everywhere,” said Greg Kraios, 250ok founder and CEO. “When I first met Mark Briggs, Validity’s CEO, I knew there was an opportunity to have a new conversation about the email industry and where it should be headed. Now as part of Validity, together we can drive innovation and excellence for everyone in the email ecosystem.”
With the acquisition of 250ok, Validity continues to expand its market presence and broaden its portfolio of leading solutions for sales and marketing professionals. Over the last two years, Validity has made the following significant acquisitions:
- CRMfusion, the leading application for enterprise CRM data quality
- BriteVerify, the most trusted global platform for email verification
- Return Path, the global leader in keeping email out of the spam folder
- AppBuddy, the top grid application for Salesforce and other platforms, and
- 250ok, the leading email analytics platform
Financial terms of the deal were not disclosed. For more information about 250ok, visit https://250ok.com .
About Validity
For over 20 years, tens of thousands of organizations across the world have relied on Validity solutions to target, contact, engage, and retain customers – using trustworthy data as a key advantage. Validity’s flagship products – DemandTools , BriteVerify , Return Path , Trust Assessments and GridBuddy – are all highly rated, #1 solutions for CRM data management, email address verification, inbox deliverability and avoiding the spam folder, and grid CRM applications. These solutions deliver smarter campaigns, more qualified leads, more productive sales, and ultimately faster growth. For more information, visit Validity.com and connect with us on LinkedIn , Instagram and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200227005774/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom